Study of XL999 in Patients With Metastatic Renal Cell Carcinoma

NCT00277316 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

11

Enrollment

INDUSTRY

Sponsor class

Stopped Development of XL999 was stopped due to cardiac toxicities in the subjects

Conditions

Renal Cell Carcinoma

Interventions

DRUG: XL999

Sponsor

Symphony Evolution, Inc.